Latest news and press releases about CalciMedica, Inc. (CALC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
Price
| Price | $1.98 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -14601.07 |
| EV / EBITDA | -3521.14 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 445.14% |
| Return on Invested Capital | -209.07% |
| Return on Assets | -217.51% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATNM · ELUT · LTRN · LVTX · MAIA · PDSB · RNXT
Explore sector: Healthcare · Biotechnology
More sections of CALC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks